tiprankstipranks
Lisata Therapeutics (LSTA)
NASDAQ:LSTA
Holding LSTA?
Track your performance easily

Lisata Therapeutics (LSTA) Earnings Date & Reports

1,029 Followers

Earnings Data

Report Date
Mar 27, 2025
TBA Not Confirmed
Period Ending
2024 (Q4)
Consensus EPS Forecast
-$0.76
Last Year’s EPS
-$0.66
Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:Nov 12, 2024
|
% Change Since: -6.87%
|
Next Earnings Date:Mar 27, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements in reducing operating expenses and advancing clinical trials, particularly the ASCEND and BOLSTER trials. However, challenges remain with increased administrative costs, slower-than-expected trial enrollment, and continued net losses.
Company Guidance
During the Lisata Therapeutics Q3 2024 earnings call, guidance was provided across several key metrics and strategic directions. The company reported operating expenses of $5.3 million, a 10.5% decrease compared to Q3 2023, with research and development expenses dropping by 24.8% to $2.5 million. General and administrative expenses rose slightly by 8.1% to $2.8 million. Lisata ended the quarter with $35.9 million in cash, cash equivalents, and marketable securities, projecting sufficient capital to fund operations into early 2026. The company's development strategy centers on certepetide, with multiple clinical trials underway, including the ASCEND trial for metastatic pancreatic ductal adenocarcinoma and the BOLSTER trial for cholangiocarcinoma. Additionally, significant regulatory achievements were highlighted, such as orphan drug designation for certepetide by the FDA. Looking ahead, Lisata anticipates key data readouts from ongoing trials, which they hope will positively impact their market valuation.
Decrease in Operating Expenses
Operating expenses totaled $5.3 million for Q3 2024, down from $6 million in Q3 2023, representing a decrease of $0.6 million or 10.5%.
Reduction in R&D Expenses
Research and development expenses decreased by $0.8 million or 24.8%, primarily due to reduced clinical research organization expenses and lower equity expense.
Orphan Drug Designation for Certepetide
Certepetide was granted orphan drug designation by the U.S. FDA for the treatment of cholangiocarcinoma.
Strong Cash Position
As of September 30, 2024, Lisata had cash, cash equivalents, and marketable securities of approximately $35.9 million.
ASCEND Trial Progress
The ASCEND trial in metastatic pancreatic ductal adenocarcinoma reached a predetermined number of events, and an abstract was accepted for presentation at ASCO GI in January 2025.
BOLSTER Trial Enrollment Success
First-line cholangiocarcinoma cohort completed enrollment nearly 6 months ahead of schedule.
---

Lisata Therapeutics (LSTA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

LSTA Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 27, 20252024 (Q4)
-0.76 / -
-0.66
Nov 12, 20242024 (Q3)
-0.75 / -0.59
-0.659.23% (+0.06)
Aug 12, 20242024 (Q2)
-0.75 / -0.61
-0.5-22.00% (-0.11)
May 09, 20242024 (Q1)
-0.72 / -0.65
-0.7715.58% (+0.12)
Feb 29, 20242023 (Q4)
-0.85 / -0.66
-0.7613.16% (+0.10)
Nov 02, 20232023 (Q3)
-0.93 / -0.65
-7.8891.75% (+7.23)
Aug 14, 20232023 (Q2)
-0.70 / -0.50
-1.6569.70% (+1.15)
May 09, 20232023 (Q1)
-0.81 / -0.77
-1.0526.67% (+0.28)
Mar 30, 20232022 (Q4)
-0.96 / -0.76
-1.6553.94% (+0.89)
Nov 10, 20222022 (Q3)
-1.27 / -7.88
-1.8-337.78% (-6.08)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

LSTA Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 12, 2024$2.91$2.79-4.12%
Aug 12, 2024$2.93$2.94+0.34%
May 09, 2024$2.91$2.95+1.37%
Feb 29, 2024$2.93$3.10+5.80%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Lisata Therapeutics (LSTA) report earnings?
Lisata Therapeutics (LSTA) is schdueled to report earning on Mar 27, 2025, TBA Not Confirmed.
    What is Lisata Therapeutics (LSTA) earnings time?
    Lisata Therapeutics (LSTA) earnings time is at Mar 27, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is LSTA EPS forecast?
          LSTA EPS forecast for the fiscal quarter 2024 (Q4) is -$0.76.
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis